Home | Blog | Weight Loss | Is Nevolat the most affordable GLP-1?
Nevolat is a GLP-1 agonist, an injectable weight loss treatment that works in the same way as Saxenda and contains the same active ingredient, liraglutide.
Nevolat might be a more affordable option as it’s a generic medication. Generic medications are often cheaper than branded versions because there are less marketing and advertising costs involved.

That said, other more expensive weight loss injections have been shown to perform better in clinical trials – and may help you reach your target weight sooner. This may mean you spend fewer months using (and buying) repeat doses, and reduce the overall cost of treatment over time.
So there are a few factors to consider when comparing the costs of using Nevolat instead of other weight loss injections.
Before you choose a weight loss injection, you might want to look at how much it will cost compared to other available treatments.
The amount of time you use a treatment for, how much weight you want to lose, and how often you need to top up your medication can all factor into what you’ll spend during your plan.
Here are some reasons why choosing Nevolat might work out cheaper than other GLP-1s.
Nevolat is the ‘generic’ equivalent of Saxenda. Generic medications work the same as the originals and are usually cheaper. This is often because when a medication’s patent expires, more manufacturers start to make it and the cost of generic versions tends to decrease.
The initial cost of using Nevolat might be similar to other GLP-1s, but you’ll reach the maintenance dose of 3mg a day after using the pen for only five weeks. This is different from Wegovy and Mounjaro, where the doses increase monthly.
Once you’re using the 3mg Nevolat pen, you’ll remain on this dose each day throughout your treatment. This means you won’t switch to a more expensive pen. You’ll need to switch pens every six days, but in theory, the cost of each pen should be the same throughout your whole Nevolat treatment plan. With Mounjaro and Wegovy, the cost of the pens rises as the doses go up.
We say ‘in theory’ because this scenario doesn’t take into account the possibility of Nevolat prices being increased as a whole during the course of your treatment. Certain factors, such as the availability of the treatment or the components required to make it or distribution costs, can prompt drug manufacturers to increase their prices.
If you’re prescribed Nevolat, you’ll start on a daily dose of 0.6mg, which will increase by 0.6mg each week until week five, where you’ll have reached the maximum daily dose of 3mg.
Nevolat pens are pre-filled, however, which means you’ll change the dose each week using the dose selector rather than ordering a fresh pen. And because of the dose titration (meaning you gradually move up through the doses), the first pen you order will last longer than the second, and so forth, because you’re injecting less medication in the first week than you are in subsequent weeks. Once you reach the maintenance dose of 3mg, each pen will last for six days.
So at the maintenance dose of 3mg a day, you’d need five pens for a month’s (30 days) supply of medication, but this price won’t increase again for the rest of your treatment plan.
For example, here are the differences between doses of Mounjaro using Treated prices as a reference:
Nevolat is available from Treated in packs of either three, or five pens:
So at the 3mg maintenance dose, a five-pack of Nevolat pens would cost you £279.95 and last for 30 days, which is the same cost as a month’s worth of the 2.5mg and 5mg strength Mounjaro pens.
People might find that the 5mg dose of Mounjaro works well enough as a maintenance dose, and decide to stay on it. But following the typical treatment plan, you’d move up to the 7.5mg dose pen and higher, which means per month you would start paying more than you would using Nevolat.
And here are the different costs between the different doses of Wegovy:
Like the 5mg dose of Mounjaro, people using Wegovy might find that the 1.7mg strength pen works well as a maintenance dose, in which case a month’s supply would cost roughly the same as a month’s supply of Nevolat at maintenance dose. But there is a higher strength 2.4mg Wegovy pen which you would usually be advised to move up to, so this is something to consider when thinking of the costs involved.
Using our current prices, here is a breakdown of what using Nevolat for 72 weeks would look like compared with Mounjaro and Wegovy as they are typically prescribed.
Efficacy rates for GLP-1s such as semaglutide, tirzepatide and liraglutide have been measured in 72-week clinical trials. So we’ve used 72 weeks as our benchmark for stopping treatment.
Nevolat overall cost after 72 weeks: £4649.15
A pack of three pens at £169.95 would last you for your first month of treatment as you move up through the doses. After this, you’ll need five pens a month (six days per pen), and the cost of five pens is £279.95.
Wegovy overall cost after 72 weeks: £5519.10
If you’re using Wegovy and follow the typical dosage titration, a month’s supply will cost £169.95 for the first three months. The price will then increase to £249.95 for the fourth month, and then £339.95 for each subsequent month in your treatment plan.
Mounjaro overall cost after 72 weeks: £7619.10
This cost is based on buying one pen at a time. For the first eight weeks of treatment, you’ll typically use the 2.5mg and 5mg Mounjaro pens, which cost £279.95 each. This increases to 7.5mg and 10mg (£379.95 per pen) for months three and four. In month five you’ll use 12.5mg and from month six onwards, you’ll use 15mg (£449.95 per pen).
These costs are also based on moving up through the doses as Mounjaro is usually prescribed. The 12.5mg and 15mg dose pens cost £449.95 each, but you might find that the 10mg pens work well enough as a maintenance dose.
You may also be able to save money by buying more than one pen at a time.
When used for 72 weeks, tirzepatide (Mounjaro) was shown to be more effective than semaglutide (Wegovy) for weight loss in clinical trials. While it might not work as effectively as both of these treatments, a 56-week study found that Nevolat helped people lose an average weight loss of 8.4kg.
As we’ve seen in the cost breakdowns above, there is a price cap for what you’ll pay each month for Nevolat, due to a ‘lower ceiling’ on dose increases; once you reach 3mg, you can’t go any higher.
When someone reaches the 1mg dose of Wegovy, or the 7.5mg dose of Mounjaro, they might have been counting on staying on this as a maintenance dose. But they could find this amount doesn’t give them the rate of weight loss they want, and so feel as though they have to increase the strength of their pen. This is another thing to consider with Nevolat – there’s only one maintenance dose, so you can rely on the ongoing price being the same.
Nevolat has the potential to be more expensive than Wegovy and Mounjaro in some cases. If you use it for a much longer period of time than you would potentially use other GLP-1s for, then over time it could ultimately cost you more.
Understanding the costs of each injection can give you a clearer picture of what you’ll spend across your entire weight loss plan. But even with the prices of each option in mind, the length of time you use a treatment for will ultimately determine your overall costs.
So if you have a fixed idea of how much weight you want to lose, choosing Wegovy or Mounjaro and using them for a shorter period of time might be the most effective option for losing weight quickly.
It’s also worth considering the pharmacy you get your weight loss medication from — prices of treatments can vary across different services — and this is another way Nevolat can potentially be more expensive than other treatments.
Usually though, Nevolat will be priced lower than other options, and as we’ve discussed, the price per pen won’t increase. And although studies have shown it reduces initial body weight at a lower rate than other GLP-1s, it’s still an effective weight loss treatment that could end up saving you money.
How we source info.
When we present you with stats, data, opinion or a consensus, we’ll tell you where this came from. And we’ll only present data as clinically reliable if it’s come from a reputable source, such as a state or government-funded health body, a peer-reviewed medical journal, or a recognised analytics or data body. Read more in our editorial policy.
Have a subject you’d like us to cover in a future article? Let us know.
We're making healthcare more about you. Sign up to our newsletter for personalised health articles that make a difference.
Disclaimer: The information provided on this page is not a substitute for professional medical advice, diagnosis, or treatment. If you have any questions or concerns about your health, please talk to a doctor.
We couldn't find what you're looking for.
Here's everything we treat. Or, if you're looking for something we don't have yet, you can suggest something.
By clicking 'Subscribe now' you're agreeing to our Privacy Policy.
(And leave your email too, so we can let you know if we write an article based on your suggestion.)
Last updated on Oct 3, 2025.
Our experts continually monitor new findings in health and medicine, and we update our articles when new info becomes available.
Oct 03, 2025
Published by: The Treated Content Team. Medically reviewed by: Dr Alexandra Cristina Cowell, Writer & Clinical Content ReviewerHow we source info.
When we present you with stats, data, opinion or a consensus, we’ll tell you where this came from. And we’ll only present data as clinically reliable if it’s come from a reputable source, such as a state or government-funded health body, a peer-reviewed medical journal, or a recognised analytics or data body. Read more in our editorial policy.
Writer & Clinical Content Reviewer
Cristina writes content for Treated, and reviews content produced by our other writers to make sure it’s clinically accurate.
MeetHow we source info.
When we present you with stats, data, opinion or a consensus, we’ll tell you where this came from. And we’ll only present data as clinically reliable if it’s come from a reputable source, such as a state or government-funded health body, a peer-reviewed medical journal, or a recognised analytics or data body. Read more in our editorial policy.